A phase1b/2 Randomized Clinical Trial of Chemotherapy With Nab-paclitaxel/Gemcitabine/Cisplatin +/- the AXL-inhibitor Bemcentinib for Patients With Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 19 Jan 2019
Price : $35 *
At a glance
- Drugs Bemcentinib (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium
- 08 Jan 2019 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
- 08 Jan 2019 Planned primary completion date changed from 1 May 2021 to 1 Jul 2021.